Iambic Therapeutics, Inc.
Iambic Therapeutics is a company dedicated to transforming drug discovery through the integration of AI and seasoned drug hunters. Their mission is to develop superior medicines to address unmet patient needs by leveraging physics-based AI algorithms, high-throughput experimentation, and a proprietary pipeline to deliver first-in-class and best-in-class programs rapidly. They focus on innovative mechanisms of action, challenging targets, and broad therapeutic areas, aiming to create highly differentiated development candidates on a faster timeline than industry norms.
Industries
Nr. of Employees
medium (51-250)
Iambic Therapeutics, Inc.
Products
IAM1363
Irreversible small-molecule tyrosine kinase inhibitor selective for HER2 and HER2 mutants with reported >1000-fold selectivity versus EGFR, CNS penetrance, favorable PK and preclinical efficacy; progressed into Phase 1 clinical dosing.
IAM-C1
First-in-class selective small-molecule inhibitor designed to target CDK2 and CDK4 while sparing other CDKs, intended to address cell-cycle dysregulation in cancer with a potentially improved safety profile.
KIF18A lead series
Allosteric small-molecule inhibitors targeting the KIF18A kinesin motor protein with single-digit nanomolar potency in biochemical and cell assays, reported selectivity and in vivo tumor growth inhibition driven by mitotic arrest.
Undisclosed GPCR allosteric agonist program
Allosteric agonist program targeting a GPCR for a neurological indication; program details and therapeutic hypothesis are undisclosed.
IAM1363
Irreversible small-molecule tyrosine kinase inhibitor selective for HER2 and HER2 mutants with reported >1000-fold selectivity versus EGFR, CNS penetrance, favorable PK and preclinical efficacy; progressed into Phase 1 clinical dosing.
IAM-C1
First-in-class selective small-molecule inhibitor designed to target CDK2 and CDK4 while sparing other CDKs, intended to address cell-cycle dysregulation in cancer with a potentially improved safety profile.
KIF18A lead series
Allosteric small-molecule inhibitors targeting the KIF18A kinesin motor protein with single-digit nanomolar potency in biochemical and cell assays, reported selectivity and in vivo tumor growth inhibition driven by mitotic arrest.
Undisclosed GPCR allosteric agonist program
Allosteric agonist program targeting a GPCR for a neurological indication; program details and therapeutic hypothesis are undisclosed.
Services
Platform-driven discovery partnerships
Collaborative service applying physics-based AI models, high-throughput design generation and automated experiments to advance external target programs and deliver differentiated development candidates faster.
Platform-driven discovery partnerships
Collaborative service applying physics-based AI models, high-throughput design generation and automated experiments to advance external target programs and deliver differentiated development candidates faster.
Expertise Areas
- AI-driven drug discovery
- Structure-based drug design
- Small-molecule lead discovery and optimization
- High-throughput experimentation and laboratory automation
Key Technologies
- Physics-based machine learning for chemistry
- Generative flow models for biomolecular complexes
- Equivariant transformers
- Multiscale generative diffusion models